secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001615219-25-000076
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Hearings Panel grants SLRX additional extension to regain listing compliance by August 2025
--------------------------------------------------------------------------------

- Equity Standard compliance deadline extended to mid-August 2025 from late July.
- Minimum Bid Price compliance deadline extended to late August 2025 from early August.
- Company previously effected a reverse stock split within past year, affecting eligibility for standard compliance periods.
- Failure to meet milestones could result in delisting from Nasdaq.
- Company's common stock (SLRX) remains listed pending hearing process resolution.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000076/0001615219-25-000076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521925000076/flks-20250728.htm
  HTML page:      https://secwatch.observer/filing/0001615219-25-000076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer